title: Does the duration of action of angiotensin converting enzyme inhibitors affect their safety and adverse effects?
abstract: The results of more than 1600 patient years of experience with the new angiotensin converting enzyme (ACE) inhibitor, quinapril, suggest that it is safe for the treatment of hypertension and congestive heart failure. A once-daily regimen of quinapril minimizes adverse effects on renal function compared with a twice-daily regimen, and compared with enalapril. This may be because long-acting agents, or frequent doses of ACE inhibitors, produce a prolonged reduction in the glomerular filtration pressure.
authors.affiliation: Parker Davis Pharmaceutical Research Division, Warner-Lambert Co., Ann Arbor, Michigan 48105-2430.
authors.forename: G J
authors.initials: GJ
authors.lastname: Frank
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002216:Captopril / Q000009:adverse effects; D004656:Enalapril / Q000009:adverse effects; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007022:Hypotension / Q000139:chemically induced; D007546:Isoquinolines / Q000009:adverse effects; D007668:Kidney / Q000187:drug effects / Q000502:physiology; D000077583:Quinapril; D044005:Tetrahydroisoquinolines; D013997:Time Factors
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D007546:Isoquinolines; D044005:Tetrahydroisoquinolines; D004656:Enalapril; D002216:Captopril; D000077583:Quinapril